RTW Investments, LP acquired the target/assets from Aquestive Therapeutics, Inc in a acquisition on not available.
Deal value was 3000000000 Sector: Healthcare; Location: USA.
On the acquirer side, not available advised, led by Ryan Kim, Ryan Murr.
Generated by AI, original source from - Data is in progress
Aquestive Therapeutics, Inc advisor
Firm name is in progress
Found it useful? Spread the word.
Gibson Dunn advises RTW Investments in acquisition of synthetic royalty interest in Anaphylm™ and lead investment in Aquestive's $85 million offering | The Sponsor - The Sponsor
